Key Takeaways
- Record revenue, margin squeeze: Revenue hit an all-time high despite a tough environment, but gross margin fell below 50% for the first time in several quarters, landing around 43% as high-cost inventory and energy prices bit.
- Inventory is the villain, not demand: The margin compression is a carry-over story from expensive raw materials stockpiled during logistics disruptions, not a demand problem; volume grew ~32% and no orders have been cancelled.
- The 25% floor is the only hard promise: Management committed to a minimum 25% operating EBITDA margin, down from the prior 30%+ norm, and expects gross margins to stabilize back around 50% once high-cost inventory is consumed.
- Hamirpur is the next growth unlock: Environmental clearance for the new site is up for a meeting imminently; approval would put the first block on track to produce by Q4 FY2024, adding at least 15 products over four to five years.
- What to watch next quarter: Whether the high-cost inventory is fully consumed as promised, the pace of gross margin recovery toward 50%, and the outcome of the Hamirpur environmental clearance meeting.
Margin Breakdown: The Inventory Overhang
- Three-part squeeze: Margins were hit by carry-over of high-cost raw material inventory ordered during logistics crises to avoid production loss, a more than two-fold rise in domestic raw materials like carbon disulfide and alkalis, and a near-tripling of green fuel costs.
- Pass-through was partial: In the herbicide category, full raw material price increases could not be passed on; in other categories, a majority was passed, but energy costs broadly could not be.
- Customer trade-off: One large multi-industrial customer relationship was maintained at near-zero gain during the raw material spike, with management betting on future compensation, a bet they say later paid off.
- No inventory write-down: The margin decline reflects consumption of high-price raw materials, not a loss booked; all products were sold at a profit.
- Consumption timeline: The entire high-cost inventory will be utilized, consumed and sold in Q3 FY2023; inventory in absolute terms already started declining in October and November, with normalization to 70–80 days expected by March.
D K Jain: "During the last quarters there were serious problems of logistics, whatever raw material we were buying from outside India the logistic problems were too many. So, we had to order bit more of the raw material to avoid any production loss at that time the prices were high. Now, we have to carry over those inventories which is resulting us in the reduction in the margins..."
Demand & Volume: Growth Intact
- Volume up 32%: Strong volume growth underpinned the record revenue, with exports growing 56% and domestic growing 28% in the quarter.
- No cancellations: No order cancellations have been received, though Europe faced very dry conditions and an erratic monsoon in India slightly affected a few domestic molecules.
- Geopolitical insulation: The Ukraine-Russia war has had little effect as the company has no serious business in those markets.
- Seasonal inventory build: Part of the balance-sheet inventory increase is deliberate stocking of a new rice herbicide whose season runs from late Q3 through Q1 of the next year.
New Capacity & Product Pipeline
- One herbicide plant delayed: Commissioning slipped from September/October to end-November/first week of December due to late delivery of critical hastelloy-lined equipment; equipment is now in place and raw materials ordered.
- Two more Sandila blocks: One herbicide and intermediates block operational by November-end, another intermediate block in Q4 FY2023.
- Backward integration underway: An intermediate for the new rice herbicide, previously over 90% imported, is now being made in-house; work on two more intermediates is in progress to reduce import dependence.
- Export-focused product: One product commissioning this month-end or early next month is entirely for export, with registrations already held in Europe and the USA.
- Two more molecules: Two additional molecules expected to be introduced in the second half of the year.
- Sandila nearly full: The site has little remaining space; only small plants of ₹5–10 Cr each could be added, as management wants to avoid congestion for safety reasons.
D K Jain: "There is no more space maybe a very small plant here and there Rs.5 Crores - Rs.10 Crores that could be added but not much because the site is more or less full now and we don't want to get too much congested here again from the safety reasons we want it to be relatively very safe plant and with reasonable spaces between the different production grounds."
Hamirpur: The Next Leg
- Clearance meeting imminent: The project application has been accepted and was listed for presentation at the Ministry of Environment Expert Committee; management hoped for clearance in that meeting, with a decision expected imminently, but noted that if they get stuck it will get slightly delayed.
- First block timeline: If clearance is obtained, the first manufacturing block could produce something by the last quarter of FY2024, as it takes about a year to put up infrastructure and one or two blocks.
- Product pipeline: At least 15 products are planned for launch over four to five years at Hamirpur, some existing and some new, export-focused molecules that nobody or very few are making in India.
- Ramp-up profile: New capacity blocks are expected to reach ~50% utilization in the first year and ~100% in the second year, or 18–24 months from commissioning.
- Capex: A further ₹35 Cr spend is expected in the second half of FY2023, with an additional ₹20 Cr budgeted for Hamirpur, with spending expected to begin in the fourth quarter once approval is received.
D K Jain: "Tomorrow is the meeting and let us see if we don't get any serious question then we should get it cleared. That is what we are hoping, if we are stuck up here then probably it will get slightly delayed. But if you are able to clear that then we are quite hopeful that in third quarter, last quarter of FY2024 we should be able to produce something."
Revenue & Margin Outlook
- ₹1,000 Cr+ topline next year: Management stated FY2024 turnover will certainly exceed ~₹1,000 Cr because all units will be in operation by then, with new products expected to contribute around ₹100 Cr this year on a conservative basis.
- Asset turnover: Overall revenue is expected at roughly 2.5x asset turnover on the capex done, with ₹70 Cr spent last year and ₹70 Cr expected this year.
- Gross margin recovery: Further deterioration is not expected; gross margins should stabilize around 50% and improve gradually over the next two quarters, though Q3 may not yet see the benefit due to the high-cost inventory overhang.
- Operating margin reset: Management committed to a minimum 25% operating EBITDA margin, calling the prior 30%+ level "slightly optimistic" over a three-to-five-year view.
- Formulation mix: The formulation percentage of total revenue is expected to increase in line with technicals, keeping the ratio more or less the same.
- FY2025 growth drivers: The majority of growth will come from the Hamirpur site and full-capacity utilization and establishment of the eight products already added.
Anand Swarup Agarwal: "Minimum 25% level we should be able to handle. We are hoping for more but we are committing 25%."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| High-cost inventory consumption | Entire high-cost inventory utilized, consumed and sold | Q3 FY2023 |
| Inventory normalization | Inventory days return to normal 70–80 level | By March 2023 |
| Gross margin recovery | Stabilize around 50%; no further deterioration | Gradual improvement over next two quarters |
| Operating EBITDA margin floor | Minimum 25% | Ongoing, three-to-five-year view |
| Herbicide plant commissioning | Delayed plant operational | End-November/first week of December 2022 |
| Two more molecules introduced | New product launches | Second half of FY2023 |
| FY2024 topline | Certainly more than ~₹1,000 Cr | FY2024 |
| Hamirpur first block production | First manufacturing block producing | Q4 FY2024, if clearance obtained imminently |
| Hamirpur product pipeline | At least 15 products launched | Over four to five years from approval |
| Hamirpur block ramp-up | ~50% utilization Year 1, ~100% Year 2 | 18–24 months from commissioning |
| Sandila small additions | One or two small products, ~400–500 tons, ~₹30 Cr revenue | No specific timeline; registrations already held |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Revenue | ₹253 cr, +38.8% YoY |
| EBITDA | ₹55 cr |
| Gross margin | ~43%, vs ~48.5% in Q1 FY23 |
| Volume growth | ~32% YoY |
| Value growth | ~39% YoY |
| Export revenue growth | 56% YoY |
| Domestic revenue growth | 28% YoY |
| Capacity utilization (technical products) | 78% |
| New product revenue contribution | ₹30 cr in Q2; ₹52 cr in H1 FY23 |
| Raw material import dependency | 35% of total purchase; China dependency 20% of total purchase |
| High-cost inventory carried | 55% of inventory as of 30 Sep |
| Capex spent in H1 FY23 | ₹35 cr |
| FY23 capex plan | ₹70 cr on existing premises, ₹20 cr for Hamirpur |
| Total technical capacity post-expansion | 27,500 tons |
| Medium-term EBITDA margin target | ~25% (management expectation) |